You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 7, 2024

Claims for Patent: 9,506,069

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,506,069

Title:	Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization
Abstract:	Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.
Inventor(s):	Ambati; Balamurali K. (Sandy, UT), Uehara; Hironori (Salt Lake City, UT)
Assignee:	University of Utah Research Foundation (Salt Lake City, UT)
Application Number:	14/394,726
Patent Claims:	1. A method of inhibiting angiogenesis in a subject wherein the method comprises binding an antisense morpholino to a splicing site of VEGR1 mRNA in the subject wherein the splicing site is selected from the group consisting of exon13_intron13 junction, intron 13_exon14 junction, or a combination thereof such that the VEGFR1 mRNA is spliced into an sFlt-1 isoform, wherein the antisense morpholino is at least 75% identical to SEQ ID NO: 1 or is at least 75% identical to SEQ ID NO: 2. 2. The method of claim 1, wherein the antisense morpholino is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, or a combination thereof. 3. The method of claim 1 wherein the antisense morpholino has a sequence that is at least 75% identical to SEQ ID NO: 1. 4. The method of claim 1 wherein the antisense morpholino has a sequence that is at least 95% identical to SEQ ID NO: 1. 5. The method of claim 1 wherein the antisense morpholino has the sequence of SEQ ID NO: 1. 6. The method of claim 1 wherein the antisense morpholino has a sequence that is at least 75% identical to SEQ ID NO: 2. 7. The method of claim 1 wherein the antisense morpholino has a sequence that is at least 95% identical to SEQ ID NO: 2. 8. The method of claim 1 wherein the antisense morpholino has the sequence of SEQ ID NO: 2. 9. A pharmaceutical composition for inhibiting angiogenesis in a subject, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an antisense morpholino capable of binding to a splicing site of VEGR1 mRNA selected from the group consisting of exon13_intron13 junction, intron 13_exon14 junction, or a combination thereof, wherein the antisense morpholino is at least 75% identical to SEQ ID NO: 1 or is at least 75% identical to SEQ ID NO: 2. 10. The composition of claim 9, wherein the morpholino includes a member selected from the group consisting of VEGFR1.sub.--Moe13 (SEQ ID NO: 1), VEGFR1.sub.--MOi13 (SEQ ID NO: 2), or a combination thereof. 11. The composition of claim 9 wherein the antisense morpholino is at least 75% identical to SEQ ID NO: 1. 12. The composition of claim 9 wherein the antisense morpholino is at least 95% identical to SEQ ID NO: 1. 13. The composition of claim 9 wherein the antisense morpholino has the sequence of SEQ ID NO: 1. 14. The composition of claim 9 wherein the antisense morpholino is at least 75% identical to SEQ ID NO: 2. 15. The composition of claim 9 wherein the antisense morpholino is at least 95% identical to SEQ ID NO: 2. 16. The composition of claim 9 wherein the antisense morpholino has the sequence of SEQ ID NO: 2.

Details for Patent 9,506,069

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2032-04-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2032-04-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2032-04-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.